Evaluating futibatinib, EV and DV with pembrolizumab in urothelial carcinoma

Aristotelis Bamias, MD, PhD, University of Athens, Athens, Greece, discusses trials assessing pembrolizumab with the addition of novel targeted agents in patients with advanced/metastatic urothelial carcinoma (mUC), including a Phase II trial (NCT04601857) of futibatinib plus pembrolizumab. Prof. Bamias additionally provides an overview of the EV-302 trial (NCT04223856), which assessed enfortumab vedotin (EV), a nectin-4-targeting antibody-drug conjugate (ADC), with pembrolizumab, and cohort C of the RC48G001 trial (NCT04879329), which assessed disitamab vedotin (DV), a HER-2-targeting ADC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.